Rapamycin Once a Week: Where Did the Pulsed Dosing Protocol Come From?
People using rapamycin off-label for anti-aging purposes almost never take it daily like transplant patients — instead, pulsed dosing dominates, most often once a week. In our entry on rapamycin and longevity we covered the broader picture of animal research and the PEARL trial — here we focus specifically on where weekly dosing actually came from, what the PEARL trial actually tested on this question, and why the honest answer to "what's the optimal human dose" is still: we don't know for sure.
Organ transplant patients take rapamycin (sirolimus) daily, in doses set individually based on blood drug levels, because they need constant, continuous immunosuppression to prevent rejection of the transplanted organ. This is the dosing schedule behind most of the multi-year safety and side-effect data on rapamycin described in our general entry on rapamycin and longevity.
Anti-aging protocols, popularized by some longevity clinics and researchers outside transplant medicine, reject that schedule in favor of pulsed dosing — usually one relatively higher dose once a week, sometimes once every two weeks. This isn't an arbitrary marketing decision but a conclusion drawn from specific mouse studies, though — as we'll show below — translating that conclusion to humans is still largely extrapolation, not an established fact.
Still a prescription drug, not a supplement
Regardless of dosing schedule, rapamycin remains a prescription immunosuppressive drug. Using it off-label under any protocol requires a prescription and medical supervision — this article describes the state of research, not instructions for self-dosing.
The rationale: pulsing mTOR, not chronically switching it off
The mTOR kinase inhibited by rapamycin is needed for many normal physiological processes — immune function, wound healing, muscle protein synthesis. Chronic, uninterrupted mTOR inhibition, as in daily transplant dosing, means chronically limiting those processes — hence the well-known side effects: increased susceptibility to infection, lipid abnormalities, delayed wound healing.
The hypothesis behind pulsed dosing is as follows: if mTOR inhibition is brief and interrupted by long drug-free periods, cells have time to "reset" normal mTOR activity between doses, which in theory allows capturing benefits linked to periodic boosts in autophagy and reduced protein synthesis (processes tied to longevity in animal models) without maintaining chronic immunosuppression the whole time. This reasoning is mechanistically sensible but isn't itself proof — it's a rational justification for a hypothesis that needs clinical confirmation.
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Moderate evidence
Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K et al. · Nature · 2009
A classic study from the Interventions Testing Program (ITP), in which rapamycin was given to mice in their diet in a way that resulted in intermittent, not constant, drug exposure (due to the specifics of absorption of the encapsulated drug form from food). The lifespan-extension effect (9–14% depending on sex) was achieved precisely in this intermittent schedule, which became one of the arguments that continuous, daily exposure isn't necessary to obtain a lifespan benefit in mice.
Mouse dosing data isn't one single, consistent protocol
Moderate evidence
Important caveat: different studies within and outside the ITP program tested different schedules — daily dietary dosing, every-other-day dosing, short, months-long "courses" of treatment started in middle age (as in the Bitto et al. eLife 2016 study described in our general rapamycin entry). All these schedules extended mouse lifespan to some degree, suggesting the effect is relatively robust to dosing details in rodents — but that alone doesn't tell us which specific schedule (and at what relative dose) is optimal in humans.
What the PEARL trial actually tested and showed
PEARL (a crowdfunded trial coordinated by AgelessRx, published in the journal Aging in 2025) is one of the few human trials that systematically tested pulsed rapamycin dosing — not just adopted it without comparison to an alternative.
Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results
Early-stage evidence
Moel M, Harinath G, Lee V, Nyquist A, Morgan SL, Isman A, Zalzala S · Aging · 2025
115 healthy participants aged 50–85 were randomized to placebo, 5 mg of rapamycin once weekly, or 10 mg once weekly, for 48 weeks. The primary, pre-specified endpoint was change in visceral fat (DXA) — no significant difference between groups was found. In secondary analyses, women in the 10 mg group gained significantly more lean body mass (p=0.013) and reported less pain, and men in the 10 mg group had higher bone mineral density. Adverse events were similar across all three groups, with no significant safety signals over this 48-week period.
From the dosing-question perspective, PEARL gave two partial answers. First: weekly dosing at 5 and 10 mg over 48 weeks appeared safe in relatively healthy people in this age range — no serious safety signals and no significant differences in adverse events between groups. Second: differences between the 5 mg and 10 mg doses in secondary analyses (benefits mainly visible at 10 mg, not 5 mg) suggest the effect may be dose-dependent — but the trial was too small and the primary result too weak to call this settled.
What PEARL didn't test
PEARL didn't compare weekly dosing with daily dosing or with dosing every two weeks — it only tested two doses within one pre-adopted weekly schedule. It doesn't answer whether the weekly schedule is better, worse, or equivalent to other possible pulsed protocols in humans — like many other questions on this topic, that remains open.
Why the human dose is still extrapolation, not an established standard
Myth
The 5–10 mg once-weekly dosing popularized by longevity clinics is an established, well-researched anti-aging protocol based on solid human data.
Fact
In reality, this specific dose range and frequency comes from a combination of two separate sources that weren't designed specifically to determine the optimal anti-aging dose in healthy humans: transplant-medicine dosing (where the goal is stable immunosuppression, not optimizing longevity) and schedules tested in mice (where relative dose per body weight and drug metabolism differ meaningfully from humans). PEARL is the first major step toward systematically testing a specific weekly dose in humans, but it's still one trial, 48 weeks, without comparison to other schedules.
The difference between transplant dosing and anti-aging dosing isn't just about frequency — it's also an order of magnitude in dose. Transplant patients take rapamycin daily at doses adjusted to maintain a specific blood drug concentration (usually a few ng/ml, monitored by regular bloodwork). Pulsed protocols aim for a much higher momentary peak concentration, but less often — and how these two very different pharmacokinetic profiles (stable low concentration vs. a high, intermittent peak) translate into relative risk and benefit isn't fully understood pharmacologically in healthy people without transplant indications.
Kaeberlein and other researchers: a promising signal, not a decisive one
Dr. Matt Kaeberlein, a longevity researcher who publicly commented on the PEARL results, noted that the trial was too small and too low-dose to consider the results definitive — while adding that the signals (especially in women in the 10 mg group) are promising and warrant larger follow-up trials with greater statistical power.
Check your profile
Not sure which supplements actually make sense for you?
Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
What this means in practice
What's worth knowing about pulsed dosing before discussing it with a doctor
Pulsed dosing (e.g., once weekly) has mechanistic justification from mouse studies, but it isn't the only schedule that extended rodent lifespan in ITP studies
The PEARL trial is the most important source to date on the safety of weekly dosing in humans (48 weeks, 5 and 10 mg), but didn't compare it with other frequencies
Specific doses (5–10 mg/week) popular in longevity clinic protocols are largely extrapolated from transplant medicine and animal models, not the result of dedicated dose-response studies in healthy humans
The compounded form of rapamycin used in PEARL has different bioavailability than commercially produced sirolimus, limiting direct translation of results to other formulations
No long-term (beyond one year) safety data exist for any pulsed schedule in healthy, non-medically-selected people
For someone considering this topic purely out of intellectual interest, it's worth realizing that the popular numbers (5 mg, 10 mg, once weekly) aren't an "established scientific standard" in the sense that drugs with a long history of dose-response research have — they're the best available starting point, derived from a limited number of sources, still actively studied, and subject to change as larger, longer trials emerge.
Limitations of this evidence
What this article doesn't prove
No trial has shown that pulsed rapamycin dosing extends life or slows aging in healthy people — PEARL mainly assessed safety and a few health biomarkers over one year, not lifespan. It's also unknown whether weekly frequency specifically is better than other intermittent schedules, or how results from the compounded formulation used in PEARL translate to commercially produced sirolimus. Mechanistic conclusions from mouse studies are suggestive but not clinical proof in humans.
Question
Short answer
Where did once-weekly dosing come from?
From combining mouse data on intermittent exposure and transplant-medicine dosing, not dedicated dose-response studies in humans
Did PEARL confirm the optimal dose?
No — it only tested 5 and 10 mg/week against placebo, without comparing other schedules
Is weekly dosing safe?
In PEARL (48 weeks) no serious safety signals were seen, but this remains limited data
Does a higher dose (10 mg) work better than 5 mg?
Suggested by secondary analyses, not a confirmed, settled result
Is this an established medical standard?
No — it remains an actively researched area, not an established clinical protocol
Pulsed rapamycin dosing, at a glance
Our editorial recommendation
Pulsed rapamycin dosing has real mechanistic justification and preliminary, limited human safety data from the PEARL trial. But that's a very different situation from having an established, well-researched dosing protocol — the current numbers are the best available starting point, derived by extrapolation from two different contexts (transplant medicine and animal models), not from dedicated dose-response studies in healthy humans.
The fact that weekly dosing has logical justification and preliminary safety data doesn't yet make it an established standard — it makes it the best hypothesis we have, still awaiting larger and longer trials.
Dr. Anna Kowalczyk, VitMode editorial team
Frequently asked questions
The hypothesis is that intermittent dosing allows capturing some of the mechanistic benefits (periodic mTOR inhibition, boosted autophagy) without maintaining chronic immunosuppression the whole time, which would limit the side effects typical of daily transplant dosing. This is mechanistic reasoning, partly supported by mouse data — not a fully confirmed clinical fact in humans.
No — PEARL only tested these two doses in a weekly schedule against placebo, without comparing other frequencies or doses. The primary, pre-specified endpoint (visceral fat) showed no significant difference; suggestions of 10 mg being superior to 5 mg come from secondary subgroup analyses.
Not directly. Different schedules (daily in diet, every other day, short courses started in middle age) all extended mouse lifespan, suggesting the effect is robust to dosing details in rodents, but differences in drug metabolism, relative dose, and physiology between mice and humans mean specific numbers don't transfer 1:1.
Not known for certain. In PEARL, secondary-analysis benefits were mainly seen in the 10 mg group, not the 5 mg group, suggesting a possible dose dependence — but higher doses also carry greater risk of side effects typical of immunosuppression, and the optimal risk-benefit balance hasn't been established in trials of healthy people.
The compounded (pharmacy-prepared) form of rapamycin used in PEARL typically has lower bioavailability than commercially produced sirolimus — meaning the trial's results don't automatically transfer to every rapamycin formulation on the market.
No — the 48-week PEARL trial is currently one of the longest controlled trials of pulsed rapamycin dosing in a healthy population. Long-term (multi-year) safety data for this specific schedule still don't exist.
No. Rapamycin is a prescription immunosuppressive drug, and this article describes the state of scientific research, not dosing instructions. Any consideration of off-label use requires a prescription and supervision from a doctor familiar with the patient's full medical history.
PhD in Molecular Biology (University of Warsaw), 8 years researching cellular aging
Anna studied molecular biology at the University of Warsaw, then spent eight years after her PhD in a lab researching the mechanisms of cellular aging and autophagy. She stumbled into science journalism almost by accident — frustrated by how easily her field's findings get oversimplified in the media, she started a blog explaining the biology of aging in plain language. That blog became the seed of VitMode. Today Anna oversees the entire editorial process, holding every piece to the same rigor her old lab demanded: primary sources, methodology checks, and honesty about the limits of the evidence. Outside work, she's a dedicated boulderer.
